How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

799 results for

Galantamine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

122. Twenty-Five Pearls from 25 years (part 1)

provide harm data including serious adverse events that are not published elsewhere. 13 Donepezil has not been demonstrat- ed to improve outcomes of impor- tance to patients and caregivers (e.g. institutionalization or disability) Drugs for Alzheimer’s Disease [Apr-Aug 2005, issue 56]. Similarly, rivastigmine, galantamine and memantine have not been studied in terms of these important outcomes. It also concludes that acetylcholinesterase inhibitors cause gastrointestinal, muscular and other adverse

2019 Therapeutics Letter

126. Cognitive Impairment - Part 2: Diagnosis To Management

reactions may be more frequent or pronounced). Theoretically, urinary alkalizers such as carbonic anhydrase inhibitors may decrease the clearance of memantine. Other Agents There is little to no evidence at this time to support the use of any other pharmaceutical agent or herbal remedy for the treatment and/or management of the cognitive and functional manifestations of dementing illnesses. ALBERTA BLUE CROSS SPECIAL AUTHORIZATION REQUEST FOR: DONEPEZIL/GALANTAMINE/RIVASTIGMINE In Alberta coverage

2017 Toward Optimized Practice

127. Drugs to avoid

laxatives Moxifloxacin Bacterial infections Serious toxicity such as liver and cardiac disorders Ciprofloxacin, Ofloxacin Donepezil (Aricept), Galantamine (Reminyl), Rivastigmine (Exelon), Memantine Alzheimer’s and other dementias Minimal efficacy; disproportionate adverse effects such as severe vomiting and syncope Support from caregivers and family Alemtuzumab (Lemtrada), Natalizumab (Tysabri), Teriflunomide (Aubagio) Multiple sclerosis Disproportionate adverse effects such as infections and liver

2018 Therapeutics Letter

128. Evidence-based Clinical Practice Guideline for Deprescribing Cholinesterase Inhibitors and Memantine

that is characterised by a progressive loss in cognition, function and behaviour [1]. Worldwide, the number of people living with dementia is increasing every year [2]. There are currently two classes of medications available to treat the symptoms of dementia: cholinesterase inhibitors (ChEIs: donepezil, rivastigmine and galantamine) and the N- methyl-D-aspartate (NMDA) receptor antagonist, memantine [3]. These medications are not disease modifying, yet they can have important benefits to people with dementia (...) and harm to the individual. Thus, the purpose of this guideline is to assist healthcare professionals (particularly prescribers) to determine when it might be suitable to trial withdrawal of these medications for an individual. These recommendations only apply to individuals already taking one of the described medications (donepezil, rivastigmine, galantamine and/or memantine). The main points of this guideline are as follows: ? A proportion of people who have used these medications for over 12 months

2018 Clinical Practice Guidelines Portal

130. Vesicular Monoamine Transporter 2 Inhibitors for Tardive Dyskinesia: Effectiveness and Value

be effective in reducing TD symptoms; the use of galantamine, eicosapentaenoic acid, and diltiazem was discouraged. Table B1 in the Appendix lists the interventions evaluated in the AAN guidelines. National Institute for Health Research 23 https://www.journalslibrary.nihr.ac.uk/hta/hta21430#/abstract A more recent systematic review sponsored by the U.K. National Institute for Health Research reported similar results. This review found insufficient evidence due to small and low-quality studies, leading

2017 California Technology Assessment Forum

131. Cochrane team criticises the ECDC experts' draft advice on oseltamivir use

agents”, had been approved for treatment of dementia in the past [8-10]. Between 1998 and 1999, most of them were taken off the market. None of the medicines approved in or before 1998 still hold a clear indication for treatment of dementia today. Currently, only 4 medicines are indicated for treatment of dementia like in other countries; namely donepezil (brand name: Aricept etc.); cholinesterase inhibitors, galantamine Abstract ?Memantine (brand name: Memary), which was launched in 2011, increases

2016 Med Check - The Informed Prescriber

132. Parkinson's disease in adults.

of dementia with Lewy bodies. 6 At the time of publication (July 2017), rivastigmine capsules are the only treatment with a UK marketing authorisation for this indication. Donepezil, galantamine and rivastigmine patches did not have a UK marketing authorisation for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's for further information. 7

2017 National Guideline Clearinghouse (partial archive)

133. Clinical practice guidelines for dementia in Australia

that the person with dementia (or their carer[s] or family) make an appointment to see a dentist to conduct an assessment and formulate a long-term treatment plan. Acetylcholinesterase inhibitors and memantine are routinely prescribed for people with mild to moderate Alzheimer disease in order to delay functional decline, and the guidelines support their use. Based on recent evidence, the guidelines also state that any one of the three acetylcholinesterase inhibitors (donepezil, galantamine or rivastigmine (...) Education Services, Department of Health and Ageing Pharmaceutical Policy Branch, Ahmed R. Post market review: Pharmaceutical Benefits Scheme anti-dementia medicines to treat Alzheimer disease. Canberra: Department of Health, 2012. (accessed Jan 2016). Birks J, Craig D. Galantamine for vascular cognitive impairment. Cochrane Database Syst Rev 2006; (1): CD004746. Birks J, McGuinness B, Craig D. Rivastigmine for vascular cognitive impairment. Cochrane Database Syst Rev 2013; (5): CD004744. Malouf R

2016 MJA Clinical Guidelines

135. Speech therapy for treatment of adults with primary progressive aphasia

stimulation on language function in patients with acquired impairments of speech, and a limited number of studies have evaluated these techniques in patients with PPA. Patient Population: Speech therapy has been evaluated in adults with PPA. Clinical Alternatives: There are no approved medical disease-modifying treatments for patients with PPA. Pharmacological interventions are of limited value, and include galantamine, memantine, amphetamine, bromocriptine, and modafinil. Other indirect interventions

2016 Health Technology Assessment (HTA) Database.

136. Stopping Donepezil may be linked to nursing home placement for people with Alzheimer’s disease, but a “cause and effect” not conclusive

the four year study period. The participants in each group had similar characteristics and stage of disease at the beginning of the trial, but we don’t know what medication they took in the last three years of the study. The authors considered that the overall trial design was representative of usual care. What does current guidance say on this issue? NICE 2011 guidance recommends donepezil (or one of the related acetyl cholinesterase inhibitors, galantamine or rivastigmine) as a medical option (...) characteristics and stage of disease at the beginning of the trial, but we don’t know what medication they took in the last three years of the study. The authors considered that the overall trial design was representative of usual care. What does current guidance say on this issue? NICE 2011 guidance recommends donepezil (or one of the related acetyl cholinesterase inhibitors, galantamine or rivastigmine) as a medical option to treat cognitive symptoms of mild to moderate Alzheimer’s disease, provided

2018 NIHR Dissemination Centre

137. Clinical practice guidelines and principles of care for people with dementia

AND MEMANTINE 69 EBR Low Any one of the three acetylcholinesterase inhibitors (donepezil, galantamine or rivastigmine) are recommended as options for managing the symptoms of mild to moderately severe Alzheimer's disease. Any one of the three acetylcholinesterase inhibitors could be considered for managing the symptoms of severe Alzheimer’s disease. 2 Prior to initiation of treatment medical practitioners should consider performing an electrocardiogram (ECG), recording weight and undertaking a falls risk

2016 Clinical Practice Guidelines Portal

140. SNMMI Procedure Standard-EANM Practice Guideline for Amyloid PET Imaging of the Brain

prescribed for dementia patients, such as donepezil, galantamine, and memantine. No drug withdrawal is recommended at this time. 2. Information Pertinent to the Procedure: Several parameters should be taken into consideration in order to improve the quality of the study acquisition and reporting: a) Correlation (preferably using digital image co-registration) with recent or concurrent morphologic imaging studies (e.g. CT, MRI) is recommended to evaluate the amount and location of brain atrophy as well

2016 Society of Nuclear Medicine and Molecular Imaging

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>